Abstract
Aims: To model the biotransformation steps of 5-FU production from capecitabine and identify patient characteristics that may influence the drug disposition. Methods: Blood samples and demographic data were collected from two phase I studies in which adult patients received oral capecitabine for various malignancies. Capecitabine, 5′-deoxy-5-fluorocytidine (5′-DFCR), 5′-deoxy-5-fluorouridine (5′-DFUR) and 5-fluorouracile (5-FU) concentration-time data were analysed via a population approach using NONMEM. Results: Forty patients and 75 pharmacokinetic time-courses were available for analysis. Capecitabine pharmacokinetics was ascribed to a one compartment model from which 5′-DFCR, 5′-DFUR and 5-FU were sequentially produced. Capecitabine oral absorption was characterized by a rapid first order input (K a =2.1 ± 0.3 hr−1) with a lag time (0.28 ± 0.11 hr), but related inter-occasion (IOV) and inter-subject (ISV) variabilities for these parameters, 167% and 110%, indicated that this oral absorption was highly variable. The capecitabine CL (CL10 = 218± 18 L/hr, ISV = 18%) and 5′-DFUR elimination rate constant (K 34 = 5.3 ± 2.0 hr−1, ISV = 25%) were influenced by total bilirubin (BILT). The elimination rate constant of plasma 5-FU (K40) was 66 ± 24 hr−1 (ISV = 34%).The final pharmacokinetic model was validated using 2000 bootstrap runs and provided non-parametric statistics of the parameters (median, 2.5th and 97.5th percentiles). Conclusions: This study supported the possibility of modelling a complex sequential metabolic pathway which produces pharmacologicaly active compounds from a prodrug. Only BILT significantly influenced the pharmacokinetics but this effect was not considered as relevant for dosing adjustment.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
B. Reigner K. Blesch E. Weidekamm (2001) ArticleTitleClinical pharmacokinetics of capecitabine Clin. Pharmacokin. 40 85–104 Occurrence Handle1:STN:280:DC%2BD3Mrks1GrtQ%3D%3D
R. Gieschke B. Reigner K.S. Blesch J.L. Steimer (2002) ArticleTitlePopulation pharmacokinetic analysis of the major metabolites of capecitabine J Pharmacokin. Pharmacodyn. 29 25–47 Occurrence Handle1:STN:280:DC%2BD38vjs1KksQ%3D%3D Occurrence Handle10.1023/A:1015716617967
R. Gieschke H.U. Burger B. Reigner K.S. Blesch J.L Steimer (2003) ArticleTitlePopulation pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients Br. J. Clin. Pharmacol. 55 252–263 Occurrence Handle10.1046/j.1365-2125.2003.01765.x Occurrence Handle12630975 Occurrence Handle1:CAS:528:DC%2BD3sXjsFylsb0%3D
B. Reigner J. Verweij L. Dirix J. Cassidy C. Twelves D Allman E. WeideKamm B. Roos L. Banken M. Utoh B. Osterwalder (1998) ArticleTitleEffect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients Clin. Cancer Res. 4 941–948 Occurrence Handle9563888 Occurrence Handle1:STN:280:DyaK1c3itlektQ%3D%3D
S.L. Beal L.B. Sheiner (1998) NONMEM User’s Guide; NONMEM project group University of California San Francisco, CA
R. Ihaka R.R. Gentleman (1996) ArticleTitleA language for data analysis and graphics J. Comput. Graphic Stat. 5 299–314
J. Parke N. Holford B. Charles (1999) ArticleTitleA procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models Comput. Methods Programs Biomed 59 19–29 Occurrence Handle10.1016/S0169-2607(98)00098-4 Occurrence Handle10215174 Occurrence Handle1:STN:280:DyaK1M3jtVSisQ%3D%3D
C. Poole J. Gardiner C. Twelves P. Johnston P. Harper J Cassidy J. Monkhouse L. Banken E. Weidekamm B. Reigner (2002) ArticleTitleEffect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients Cancer Chemother Pharmacol. 49 225–234 Occurrence Handle10.1007/s00280-001-0408-0 Occurrence Handle11935215
B. Reigner T. Watanabe J. Schuller H. Lucraft Y. Sasaki J Bridgewater T. Saeki J. McAleer M. Kuranami C. Poole M Kimura J. Monkhouse C. Yorulmaz E. Weidekamm S. Grange (2003) ArticleTitlePharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer Cancer Chemother Pharmacol. 52 193–201 Occurrence Handle10.1007/s00280-003-0642-8 Occurrence Handle12783206 Occurrence Handle1:CAS:528:DC%2BD3sXms12gtbg%3D
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Urien, S., Rezaí, K. & Lokiec, F. Pharmacokinetic Modelling of 5-FU Production from Capecitabine—A Population Study in 40 Adult Patients with Metastatic Cancer. J Pharmacokinet Pharmacodyn 32, 817–833 (2005). https://doi.org/10.1007/s10928-005-0018-2
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10928-005-0018-2